Cardiol's therapeutic approach centers on modulating inflammasome pathway activation through pharmaceutically manufactured cannabidiol formulations developed under cGMP standards. The lead oral drug candidate, CardiolRx™, is in late-stage clinical development in Phase III MAVERIC trial for recurrent pericarditis and Phase II ARCHER trial for acute myocarditis, while also advancing CRD-38, a proprietary subcutaneous cannabidiol formulation for heart failure.
Cyborg Score Rationale
The company has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial with full enrollment expected in Q2 2026. Phase II ARCHER results showed CardiolRx produced structural heart improvements in acute myocarditis with significant LV mass reduction versus placebo. Recent financing and patent protection strengthen the position.
Top Insights
MAVERIC Phase III trial for recurrent pericarditis surpassed 50% enrollment with completion expected in Q2 2026
ARCHER Phase II data demonstrated significant left ventricular mass reduction (-9.2g vs placebo, p=0.0117) in acute myocarditis
U.S. patent allowance for cannabidiol compositions in heart conditions provides protection through October 2040
Recent January 2026 private placement raised $14.85 million to advance clinical development and general operations
Named Competitors
Myokardia — Cardiac mechanics therapies for heart failure
Galera Therapeutics — Inflammation reduction in cardiovascular conditions
Akebia Therapeutics — Cardiovascular and kidney disease therapies
Recent Developments
(April 2026) Highlighted MAVERIC Phase III trial progress and published ARCHER results in investor presentations
(February 2026) ARCHER Phase II study results published in ESC Heart Failure journal demonstrating cardiac structural improvements
(January 2026) Closed $14.85 million private placement financing to advance research and development programs
(January 2026) Surpassed 50% patient enrollment in pivotal MAVERIC Phase III trial
Open the full interactive Cardiol Therapeutics Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.